Similar articles

• [Drug resistance of tubercle bacilli -- from the clinical point of view (author's transl)].

  Fukuhara Y. Fukuhara Y. Kekkaku. 1976 Dec;51(12):477-87. Kekkaku. 1976. PMID: 65494 Japanese. No abstract available.
• [Critical concentrations for resistances of tubercle bacilli to tuberactinomycin-N, viomycin, capreomycin, and lividomycin in patients treated with these agents (cross-resistance-relationships among resistances to aminoglucoside-antibiotics found during chemotherapy for tuberculosis) (author's transl)].

  Tsukamura M, Mizuno S, Murata H, Oshima T. Tsukamura M, et al. Kekkaku. 1975 May;50(4-5):123-30. Kekkaku. 1975. PMID: 49449 Japanese. No abstract available.
• [Cross resistance of tubercle bacilli to KM, VM, CPM, LVM, and TUM. II. The susceptibility of antibiotic-resistant strains which were obtained in vitro to the five antibiotics (author's transl)].

  Saito T, Fukuhara Y. Saito T, et al. Kekkaku. 1974 Apr;49(4):91-6. Kekkaku. 1974. PMID: 4137393 Japanese. No abstract available.
• [Cross resistance in mycobacteria--biochemical and genetic aspects (author's transl)].

  Mizuguchi Y, Yamada T. Mizuguchi Y, et al. Kekkaku. 1978 Apr;53(4):243-50. Kekkaku. 1978. PMID: 96293 Review. Japanese. No abstract available.
• [Action and resistance mechanisms of capreomycin: a functional genomic perspective].

  Liu XM, Xie JP. Liu XM, et al. Yao Xue Xue Bao. 2008 Aug;43(8):788-92. Yao Xue Xue Bao. 2008. PMID: 18956769 Review. Chinese.